AMVUTTRA® (vutrisiran)Just the ticket for ATTR-CM start your journey

Ask your doctor about AMVUTTRA® (vutrisiran)

Proven to help people live longer and have fewer heart‑related hospital visits*

*Compared to placebo over 3 years. Included hospital stays and urgent visits.
The first and only silencer for ATTR-CM that works to rapidly knock down TTR at the source†
†Reduced transthyretin (TTR) as early as 6 weeks.

Learn how it works

Safety and effectiveness shown in a clinical study of 654 adults with ATTR-CM

Explore the results

4 doses a year given as an injection every 3 months by a healthcare provider

Get dosing details

†Reduced transthyretin (TTR) as early as 6 weeks.

Stay informed about ATTR‑CM and AMVUTTRA

Receive emails with the latest information, educational resources, and answers to commonly asked questions. 

Sign up

 

Explore savings and support opportunities

Alnylam can help you understand your insurance coverage and whether you’re eligible for financial assistance.

Learn more

ENVISION A DIFFERENT JOURNEY

00:00

 
 

 

IMPORTANT SAFETY INFORMATION

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.  

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR‑CM) in adults to reduce heart-related death, hospital stays and urgent visits.
  • polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR‑PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Footer Waves Left Footer Waves Right